Combination of antiangiogenic therapy using the mTOR [mammalian target of rapamycin]-inhibitor RAD001 [everolimus] and low dose chemotherapy [gemcitabine] for locally advanced and/or metastatic pancreatic cancer - a dose finding study.

Trial Profile

Combination of antiangiogenic therapy using the mTOR [mammalian target of rapamycin]-inhibitor RAD001 [everolimus] and low dose chemotherapy [gemcitabine] for locally advanced and/or metastatic pancreatic cancer - a dose finding study.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 14 Nov 2012

At a glance

  • Drugs Everolimus (Primary) ; Gemcitabine (Primary)
  • Indications Pancreatic cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 14 Nov 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 07 Feb 2012 Actual patient number 21 added as reported by ClinicalTrials.gov.
    • 18 Jan 2011 Planned End Date dded to 1 Apr 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top